Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Oct 28

PMID 37892713

Authors

Silvia Ferrucci

Giovanni Casazza

Martina Zussino

Simona Tavecchio

Angelo V Marzano

Micol Tedeschi

Affiliations

Soon will be listed here.

Abstract

Efforts have been made to identify factors influencing clinical response in patients with atopic dermatitis (AD) treated with dupilumab. A retrospective single-center observational study was carried out by analyzing data from 492 patients aged 12 years and older with moderate-to-severe AD. The study aimed to identify baseline demographic and clinical factors that could predict the achievement of a mild level of disease, i.e., an Eczema Area and Severity Index (EASI) ≤ 7, within 4 weeks from dupilumab initiation. Classic, generalized lichenoid and inflammatory phenotypes compared with a nummular eczema phenotype (OR = 6.9, 95% CI 2.04-23.48 and OR = 4.22, 95% CI 1.22-14.66, respectively) and a baseline EASI ≤ 24 and between 24-29, compared with a baseline EASI ≥ 29 (OR = 3.1, 95% CI 1.81-5.41 and OR = 1.8, 95% CI 1.05-3.07, respectively), were found to be predictive factors of early response to dupilumab, highlighting the importance of early biological treatment of AD.

References

Napolitano M, Fabbrocini G, Neri I, Stingeni L, Boccaletti V, Piccolo V . Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study. Paediatr Drugs. 2022; 24(6):671-678. PMC: 9417930. DOI: 10.1007/s40272-022-00531-0. View

Akdis C . Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?. Nat Rev Immunol. 2021; 21(11):739-751. DOI: 10.1038/s41577-021-00538-7. View

Nettis E, Ferrucci S, Ortoncelli M, Pellacani G, Foti C, Di Leo E . Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study. J Investig Allergol Clin Immunol. 2020; 32(2):124-132. DOI: 10.18176/jiaci.0641. View

Le Floch A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S . Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2019; 75(5):1188-1204. PMC: 7317958. DOI: 10.1111/all.14151. View

Napolitano M, Fabbrocini G, Potestio L, Fontanella G, Picone V, Bennardo L . A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis. Dermatol Ther. 2022; 35(8):e15588. DOI: 10.1111/dth.15588. View

Pappa G, Sgouros D, Theodoropoulos K, Kanelleas A, Bozi E, Gregoriou S . The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis. J Clin Med. 2022; 11(19). PMC: 9570949. DOI: 10.3390/jcm11195633. View

Simpson E, Bieber T, Guttman-Yassky E, Beck L, Blauvelt A, Cork M . Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016; 375(24):2335-2348. DOI: 10.1056/NEJMoa1610020. View

Silvestre Salvador J, Romero-Perez D, Encabo-Duran B . Atopic Dermatitis in Adults: A Diagnostic Challenge. J Investig Allergol Clin Immunol. 2017; 27(2):78-88. DOI: 10.18176/jiaci.0138. View

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson E, Blauvelt A, Cork M . Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019; 181(3):459-473. PMC: 6850316. DOI: 10.1111/bjd.17869. View

10.

Nettis E, Bonzano L, Patella V, Detoraki A, Trerotoli P, Lombardo C . Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis: A Multicenter Real-Life Experience. J Investig Allergol Clin Immunol. 2020; 30(3):201-204. DOI: 10.18176/jiaci.0481. View

11.

Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L . Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019; 181(4):761-769. PMC: 6850643. DOI: 10.1111/bjd.17744. View

12.

Badia X, Mascaro J, Lozano R . Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999; 141(4):698-702. DOI: 10.1046/j.1365-2133.1999.03112.x. View

13.

Ferrucci S, Angileri L, Tavecchio S, Fumagalli S, Iurlo A, Cattaneo D . Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease. J Dermatolog Treat. 2022; 33(5):2587-2592. DOI: 10.1080/09546634.2022.2049588. View

14.

Paller A, Bansal A, Simpson E, Boguniewicz M, Blauvelt A, Siegfried E . Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2019; 21(1):119-131. PMC: 6989562. DOI: 10.1007/s40257-019-00478-y. View

15.

Hanifin J, Thurston M, Omoto M, Cherill R, Tofte S, Graeber M . The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001; 10(1):11-8. DOI: 10.1034/j.1600-0625.2001.100102.x. View

16.

Wollenberg A, Beck L, Blauvelt A, Simpson E, Chen Z, Chen Q . Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2019; 182(5):1120-1135. PMC: 7317598. DOI: 10.1111/bjd.18434. View

17.

Paller A, Siegfried E, Thaci D, Wollenberg A, Cork M, Arkwright P . Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020; 83(5):1282-1293. DOI: 10.1016/j.jaad.2020.06.054. View

18.

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32(5):657-682. DOI: 10.1111/jdv.14891. View

19.

Nettis E, Ferrucci S, Pellacani G, Di Leo E, Argenziano G, Foti C . Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response. J Eur Acad Dermatol Venereol. 2021; 35(12):e896-e898. DOI: 10.1111/jdv.17541. View

20.

Paller A, Simpson E, Siegfried E, Cork M, Wollenberg A, Arkwright P . Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022; 400(10356):908-919. DOI: 10.1016/S0140-6736(22)01539-2. View